These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 33739437)

  • 21. A comparison of brain magnetic resonance imaging lesions in multiple sclerosis by race with reference to disability progression.
    Nakamura Y; Gaetano L; Matsushita T; Anna A; Sprenger T; Radue EW; Wuerfel J; Bauer L; Amann M; Shinoda K; Isobe N; Yamasaki R; Saida T; Kappos L; Kira JI
    J Neuroinflammation; 2018 Sep; 15(1):255. PubMed ID: 30185189
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monitoring disease activity and progression in primary progressive multiple sclerosis using MRI: sub-voxel registration to identify lesion changes and to detect cerebral atrophy.
    Stevenson VL; Smith SM; Matthews PM; Miller DH; Thompson AJ
    J Neurol; 2002 Feb; 249(2):171-7. PubMed ID: 11985382
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Progression of regional grey matter atrophy in multiple sclerosis.
    Eshaghi A; Marinescu RV; Young AL; Firth NC; Prados F; Jorge Cardoso M; Tur C; De Angelis F; Cawley N; Brownlee WJ; De Stefano N; Laura Stromillo M; Battaglini M; Ruggieri S; Gasperini C; Filippi M; Rocca MA; Rovira A; Sastre-Garriga J; Geurts JJG; Vrenken H; Wottschel V; Leurs CE; Uitdehaag B; Pirpamer L; Enzinger C; Ourselin S; Gandini Wheeler-Kingshott CA; Chard D; Thompson AJ; Barkhof F; Alexander DC; Ciccarelli O
    Brain; 2018 Jun; 141(6):1665-1677. PubMed ID: 29741648
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FLAIR-only joint volumetric analysis of brain lesions and atrophy in clinically isolated syndrome (CIS) suggestive of multiple sclerosis.
    Goodkin O; Prados F; Vos SB; Pemberton H; Collorone S; Hagens MHJ; Cardoso MJ; Yousry TA; Thornton JS; Sudre CH; Barkhof F;
    Neuroimage Clin; 2021; 29():102542. PubMed ID: 33418171
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of gadolinium-based contrast-agents on automated brain atrophy measurements by FreeSurfer in patients with multiple sclerosis.
    Lie IA; Kerklingh E; Wesnes K; van Nederpelt DR; Brouwer I; Torkildsen Ø; Myhr KM; Barkhof F; Bø L; Vrenken H
    Eur Radiol; 2022 May; 32(5):3576-3587. PubMed ID: 34978580
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relaxometry and brain myelin quantification with synthetic MRI in MS subtypes and their associations with spinal cord atrophy.
    Ladopoulos T; Matusche B; Bellenberg B; Heuser F; Gold R; Lukas C; Schneider R
    Neuroimage Clin; 2022; 36():103166. PubMed ID: 36081258
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Impact of MRI T1 Hypointense Brain Lesions on Cerebral Deep Gray Matter Volume Measures in Multiple Sclerosis.
    Buyukturkoglu K; Mormina E; De Jager PL; Riley CS; Leavitt VM
    J Neuroimaging; 2019 Jul; 29(4):458-462. PubMed ID: 30892794
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of volumetric MRI measures and disability in MS patients of the same age: Descriptions from a birth year cohort.
    de Ruiter LRJ; Loonstra FC; Jelgerhuis JR; Coerver EME; Toorop AA; van Leeuwen ICE; Noteboom S; Moraal B; Strijbis EMM; Schoonheim MM; Uitdehaag BMJ
    Mult Scler Relat Disord; 2023 Mar; 71():104568. PubMed ID: 36805177
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis.
    Cagol A; Schaedelin S; Barakovic M; Benkert P; Todea RA; Rahmanzadeh R; Galbusera R; Lu PJ; Weigel M; Melie-Garcia L; Ruberte E; Siebenborn N; Battaglini M; Radue EW; Yaldizli Ö; Oechtering J; Sinnecker T; Lorscheider J; Fischer-Barnicol B; Müller S; Achtnichts L; Vehoff J; Disanto G; Findling O; Chan A; Salmen A; Pot C; Bridel C; Zecca C; Derfuss T; Lieb JM; Remonda L; Wagner F; Vargas MI; Du Pasquier R; Lalive PH; Pravatà E; Weber J; Cattin PC; Gobbi C; Leppert D; Kappos L; Kuhle J; Granziera C
    JAMA Neurol; 2022 Jul; 79(7):682-692. PubMed ID: 35575778
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Do subcortical gray matter volumes and aerobic capacity account for cognitive-motor coupling in multiple sclerosis?
    Motl RW; Sandroff BM; Benedict RH; Hubbard EA; Pilutti LA; Sutton BP
    Mult Scler; 2021 Mar; 27(3):401-409. PubMed ID: 32228278
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cognitive processing speed in multiple sclerosis clinical practice: association with patient-reported outcomes, employment and magnetic resonance imaging metrics.
    Macaron G; Baldassari LE; Nakamura K; Rao SM; McGinley MP; Moss BP; Li H; Miller DM; Jones SE; Bermel RA; Cohen JA; Ontaneda D; Conway DS
    Eur J Neurol; 2020 Jul; 27(7):1238-1249. PubMed ID: 32222019
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of multiple sclerosis patients at highest risk of cognitive impairment using an integrated brain magnetic resonance imaging assessment approach.
    Uher T; Vaneckova M; Sormani MP; Krasensky J; Sobisek L; Dusankova JB; Seidl Z; Havrdova E; Kalincik T; Benedict RH; Horakova D
    Eur J Neurol; 2017 Feb; 24(2):292-301. PubMed ID: 27873386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advanced diffusion-weighted imaging models better characterize white matter neurodegeneration and clinical outcomes in multiple sclerosis.
    Storelli L; Pagani E; Meani A; Preziosa P; Filippi M; Rocca MA
    J Neurol; 2022 Sep; 269(9):4729-4741. PubMed ID: 35397753
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Brain microstructural and metabolic alterations detected in vivo at onset of the first demyelinating event.
    Collorone S; Prados F; Kanber B; Cawley NM; Tur C; Grussu F; Solanky BS; Yiannakas M; Davagnanam I; Wheeler-Kingshott CAMG; Barkhof F; Ciccarelli O; Toosy AT
    Brain; 2021 Jun; 144(5):1409-1421. PubMed ID: 33903905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuroinflammation and its relationship to changes in brain volume and white matter lesions in multiple sclerosis.
    Datta G; Colasanti A; Rabiner EA; Gunn RN; Malik O; Ciccarelli O; Nicholas R; Van Vlierberghe E; Van Hecke W; Searle G; Santos-Ribeiro A; Matthews PM
    Brain; 2017 Nov; 140(11):2927-2938. PubMed ID: 29053775
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation of clinical findings and brain volume data in multiple sclerosis.
    Fragoso YD; Wille PR; Abreu M; Brooks JBB; Dias RM; Duarte JA; Farage L; Finkelsztejn A; Frohlich AC; Goncalves MVM; Guedes BVS; Medeiros L; Oliveira RA; Ribas FD; da Rocha FCG; Santos GAC; Scorcine C; da Silveira GL; Spedo CT; Tauil CB; Varela JS; Vieira VLF;
    J Clin Neurosci; 2017 Oct; 44():155-157. PubMed ID: 28676309
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes.
    Dalton CM; Chard DT; Davies GR; Miszkiel KA; Altmann DR; Fernando K; Plant GT; Thompson AJ; Miller DH
    Brain; 2004 May; 127(Pt 5):1101-7. PubMed ID: 14998914
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Spatial distribution of multiple sclerosis lesions in the cervical spinal cord.
    Eden D; Gros C; Badji A; Dupont SM; De Leener B; Maranzano J; Zhuoquiong R; Liu Y; Granberg T; Ouellette R; Stawiarz L; Hillert J; Talbott J; Bannier E; Kerbrat A; Edan G; Labauge P; Callot V; Pelletier J; Audoin B; Rasoanandrianina H; Brisset JC; Valsasina P; Rocca MA; Filippi M; Bakshi R; Tauhid S; Prados F; Yiannakas M; Kearney H; Ciccarelli O; Smith SA; Andrada Treaba C; Mainero C; Lefeuvre J; Reich DS; Nair G; Shepherd TM; Charlson E; Tachibana Y; Hori M; Kamiya K; Chougar L; Narayanan S; Cohen-Adad J
    Brain; 2019 Mar; 142(3):633-646. PubMed ID: 30715195
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of deep grey matter volume on cognition in multiple sclerosis.
    Lorefice L; Carta E; Frau J; Contu F; Casaglia E; Coghe G; Barracciu MA; Cocco E; Fenu G
    Mult Scler Relat Disord; 2020 Oct; 45():102351. PubMed ID: 32731200
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fingolimod's Impact on MRI Brain Volume Measures in Multiple Sclerosis: Results from MS-MRIUS.
    Zivadinov R; Medin J; Khan N; Korn JR; Bergsland N; Dwyer MG; Chitnis T; Naismith RT; Alvarez E; Kinkel P; Cohan S; Hunter SF; Silva D; Weinstock-Guttman B;
    J Neuroimaging; 2018 Jul; 28(4):399-405. PubMed ID: 29749661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.